{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T06:00:05Z","timestamp":1787032805811,"version":"build-2736575974"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,28]]},"DOI":"10.7759\/cureus.42614","type":"journal-article","created":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T10:54:32Z","timestamp":1690541672000},"source":"Crossref","is-referenced-by-count":10,"title":["Novel Therapeutic Targets for Fibrodysplasia Ossificans Progressiva: Emerging Strategies and Future Directions"],"prefix":"10.7759","author":[{"given":"Usman","family":"Shaikh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anoosha","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anzal","family":"Ishfaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chukwuyem","family":"Ekhator","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paras","family":"Yousuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghu","family":"Halappa Nagaraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Raza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ubaid","family":"Ur Rehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Uzair","family":"Zaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautham","family":"Lakshmipriya Vetrivendan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nhan","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijan","family":"Kadel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tenzin N","family":"Sherpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf","family":"Ullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia B","family":"Bellegarde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1677\/JOE-07-0281","article-title":"Activin receptor-like kinase-2 inhibits activin signaling by blocking the binding of activin to its type II receptor","volume":"195","author":"Renlund N","year":"2007","unstructured":"Renlund N, O'Neill FH, Zhang L, Sidis Y, Teixeira J. Activin receptor-like kinase-2 inhibits activin signaling by blocking the binding of activin to its type II receptor. J Endocrinol. 2007, 195:95-103. 10.1677\/JOE-07-0281","journal-title":"J Endocrinol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115539","article-title":"Fibrodysplasia ossificans progressiva (FOP): a disorder of osteochondrogenesis","volume":"140","author":"Kaplan FS","year":"2020","unstructured":"Kaplan FS, Al Mukaddam M, Stanley A, Towler OW, Shore EM. Fibrodysplasia ossificans progressiva (FOP): a disorder of osteochondrogenesis. Bone. 2020, 140:115539. 10.1016\/j.bone.2020.115539","journal-title":"Bone"},{"key":"ref3","article-title":"Fibrodysplasia ossificans progressiva","author":"Agrawal U","year":"2023","unstructured":"Agrawal U, Tiwari V. Fibrodysplasia ossificans progressiva. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2017.07.024","article-title":"Heterotopic bone induction via BMP signaling: potential therapeutic targets for fibrodysplasia ossificans progressiva","volume":"109","author":"Katagiri T","year":"2018","unstructured":"Katagiri T, Tsukamoto S, Kuratani M. Heterotopic bone induction via BMP signaling: potential therapeutic targets for fibrodysplasia ossificans progressiva. Bone. 2018, 109:241-50. 10.1016\/j.bone.2017.07.024","journal-title":"Bone"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-019-2297-z","article-title":"Fibrodysplasia ossificans progressiva (stone man syndrome): a case report","volume":"13","author":"Shah ZA","year":"2019","unstructured":"Shah ZA, Rausch S, Arif U, El Yafawi B. Fibrodysplasia ossificans progressiva (stone man syndrome): a case report. J Med Case Rep. 2019, 13:364. 10.1186\/s13256-019-2297-z","journal-title":"J Med Case Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2012-006422","article-title":"The stone man disease: fibrodysplasia ossificans progressiva: imaging revisited","volume":"2012","author":"Verma AK","year":"2012","unstructured":"Verma AK, Aga P, Singh SK, Singh R. The stone man disease: fibrodysplasia ossificans progressiva: imaging revisited. BMJ Case Rep. 2012, 2012:10.1136\/bcr-2012-006422","journal-title":"BMJ Case Rep"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10010140","article-title":"Editorial of special issue \"Fibrodysplasia ossificans progressiva: studies on disease mechanism towards novel therapeutic approaches\"","volume":"10","author":"Ravazzolo R","year":"2022","unstructured":"Ravazzolo R. Editorial of special issue \"Fibrodysplasia ossificans progressiva: studies on disease mechanism towards novel therapeutic approaches\". Biomedicines. 2022, 10:140. 10.3390\/biomedicines10010140","journal-title":"Biomedicines"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13823","article-title":"Therapeutic advances for blocking heterotopic ossification in fibrodysplasia ossificans progressiva","volume":"85","author":"Wentworth KL","year":"2019","unstructured":"Wentworth KL, Masharani U, Hsiao EC. Therapeutic advances for blocking heterotopic ossification in fibrodysplasia ossificans progressiva. Br J Clin Pharmacol. 2019, 85:1180-7. 10.1111\/bcp.13823","journal-title":"Br J Clin Pharmacol"},{"key":"ref9","article-title":"Fibrodysplasia ossificans progressiva: diagnosis, management, and therapeutic horizons","volume":"10","author":"Pignolo RJ","year":"2013","unstructured":"Pignolo RJ, Shore EM, Kaplan FS. Fibrodysplasia ossificans progressiva: diagnosis, management, and therapeutic horizons. Pediatr Endocrinol Rev. 2013, 10:437-48.","journal-title":"Pediatr Endocrinol Rev"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5049.202168","article-title":"Anaesthetic management of a child with stone man syndrome: look before you leap!","volume":"61","author":"Kamal G","year":"2017","unstructured":"Kamal G, Gupta A, Batla S, Gupta N. Anaesthetic management of a child with stone man syndrome: look before you leap!. Indian J Anaesth. 2017, 61:266-8. 10.4103\/0019-5049.202168","journal-title":"Indian J Anaesth"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/978-90-481-9485-8_19","article-title":"Osteochondral diseases and fibrodysplasia ossificans progressiva","volume":"686","author":"Morales-Piga A","year":"2010","unstructured":"Morales-Piga A, Kaplan FS. Osteochondral diseases and fibrodysplasia ossificans progressiva. Adv Exp Med Biol. 2010, 686:335-48. 10.1007\/978-90-481-9485-8_19","journal-title":"Adv Exp Med Biol"},{"key":"ref12","doi-asserted-by":"crossref","DOI":"10.29245\/2572-9411\/2020\/2.1196","article-title":"Epidemiology of the global fibrodysplasia ossificans progressiva (FOP) community","volume":"5","author":"Liljesthr\u00f6m M","year":"2020","unstructured":"Liljesthr\u00f6m M, Pignolo RJ, Kaplan FS. Epidemiology of the global fibrodysplasia ossificans progressiva (FOP) community. J Rare Dis Res Treat. 2020, 5:","journal-title":"J Rare Dis Res Treat"},{"key":"ref13","article-title":"Fibrodysplasia ossificans progressiva","author":"Akesson LS","year":"2023","unstructured":"Akesson LS, Savarirayan R. Fibrodysplasia ossificans progressiva. GeneReviews. Adam MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJ, Gripp KW, Amemiya A (ed): University of Washington, Seattle; 2023."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.5582\/irdr.2017.01055","article-title":"Fibrodysplasia ossificans progressiva: basic understanding and experimental models","volume":"6","author":"Qi Z","year":"2017","unstructured":"Qi Z, Luan J, Zhou X, Cui Y, Han J. Fibrodysplasia ossificans progressiva: basic understanding and experimental models. Intractable Rare Dis Res. 2017, 6:242-8. 10.5582\/irdr.2017.01055","journal-title":"Intractable Rare Dis Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ydbio.2015.02.011","article-title":"BMP signaling mediated by constitutively active Activin type 1 receptor (ACVR1) results in ectopic bone formation localized to distal extremity joints","volume":"400","author":"Agarwal S","year":"2015","unstructured":"Agarwal S, Loder SJ, Brownley C, et al.. BMP signaling mediated by constitutively active Activin type 1 receptor (ACVR1) results in ectopic bone formation localized to distal extremity joints. Dev Biol. 2015, 400:202-9. 10.1016\/j.ydbio.2015.02.011","journal-title":"Dev Biol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-6-80","article-title":"Fibrodysplasia ossificans progressiva: clinical and genetic aspects","volume":"6","author":"Pignolo RJ","year":"2011","unstructured":"Pignolo RJ, Shore EM, Kaplan FS. Fibrodysplasia ossificans progressiva: clinical and genetic aspects. Orphanet J Rare Dis. 2011, 6:80. 10.1186\/1750-1172-6-80","journal-title":"Orphanet J Rare Dis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2008.05.013","article-title":"Insights from a rare genetic disorder of extra-skeletal bone formation, fibrodysplasia ossificans progressiva (FOP)","volume":"43","author":"Shore EM","year":"2008","unstructured":"Shore EM, Kaplan FS. Insights from a rare genetic disorder of extra-skeletal bone formation, fibrodysplasia ossificans progressiva (FOP). Bone. 2008, 43:427-33. 10.1016\/j.bone.2008.05.013","journal-title":"Bone"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines8090325","article-title":"Clinical aspects and current therapeutic approaches for FOP","volume":"8","author":"Kitoh H","year":"2020","unstructured":"Kitoh H. Clinical aspects and current therapeutic approaches for FOP. Biomedicines. 2020, 8:325. 10.3390\/biomedicines8090325","journal-title":"Biomedicines"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/MOP.0000000000000802","article-title":"Fibrodysplasia ossificans progressiva: lessons learned from a rare disease","volume":"31","author":"Akyuz G","year":"2019","unstructured":"Akyuz G, Gencer-Atalay K, Ata P. Fibrodysplasia ossificans progressiva: lessons learned from a rare disease. Curr Opin Pediatr. 2019, 31:716-22. 10.1097\/MOP.0000000000000802","journal-title":"Curr Opin Pediatr"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-019-00330-0","article-title":"Current and emerging therapeutic options for the management of rare skeletal diseases","volume":"21","author":"Semler O","year":"2019","unstructured":"Semler O, Rehberg M, Mehdiani N, Jackels M, Hoyer-Kuhn H. Current and emerging therapeutic options for the management of rare skeletal diseases. Paediatr Drugs. 2019, 21:95-106. 10.1007\/s40272-019-00330-0","journal-title":"Paediatr Drugs"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01406-8","article-title":"Prophylactic treatment of rapamycin ameliorates naturally developing and episode -induced heterotopic ossification in mice expressing human mutant ACVR1","volume":"15","author":"Maekawa H","year":"2020","unstructured":"Maekawa H, Kawai S, Nishio M, et al.. Prophylactic treatment of rapamycin ameliorates naturally developing and episode -induced heterotopic ossification in mice expressing human mutant ACVR1. Orphanet J Rare Dis. 2020, 15:122. 10.1186\/s13023-020-01406-8","journal-title":"Orphanet J Rare Dis"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.732728","article-title":"Fibrodysplasia ossificans progressiva: what have we achieved and where are we now? Follow-up to the 2015 Lorentz workshop","volume":"12","author":"de Ruiter RD","year":"2021","unstructured":"de Ruiter RD, Smilde BJ, Pals G, et al.. Fibrodysplasia ossificans progressiva: what have we achieved and where are we now? Follow-up to the 2015 Lorentz workshop. Front Endocrinol (Lausanne). 2021, 12:732728. 10.3389\/fendo.2021.732728","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9020213","article-title":"Challenges and opportunities for drug repositioning in fibrodysplasia ossificans progressiva","volume":"9","author":"Ventura F","year":"2021","unstructured":"Ventura F, Williams E, Ikeya M, Bullock AN, Ten Dijke P, Goumans MJ, Sanchez-Duffhues G. Challenges and opportunities for drug repositioning in fibrodysplasia ossificans progressiva. Biomedicines. 2021, 9:213. 10.3390\/biomedicines9020213","journal-title":"Biomedicines"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02224-w","article-title":"Current challenges and opportunities in the care of patients with fibrodysplasia ossificans progressiva (FOP): an international, multi-stakeholder perspective","volume":"17","author":"Pignolo RJ","year":"2022","unstructured":"Pignolo RJ, Bedford-Gay C, Cali A, et al.. Current challenges and opportunities in the care of patients with fibrodysplasia ossificans progressiva (FOP): an international, multi-stakeholder perspective. Orphanet J Rare Dis. 2022, 17:168. 10.1186\/s13023-022-02224-w","journal-title":"Orphanet J Rare Dis"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2017.10.023","article-title":"New applications of CRISPR\/Cas9 system on mutant DNA detection","volume":"641","author":"Jia C","year":"2018","unstructured":"Jia C, Huai C, Ding J, Hu L, Su B, Chen H, Lu D. New applications of CRISPR\/Cas9 system on mutant DNA detection. Gene. 2018, 641:55-62. 10.1016\/j.gene.2017.10.023","journal-title":"Gene"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-023-01011-7","article-title":"Optimization of Cas9 activity through the addition of cytosine extensions to single-guide RNAs","volume":"7","author":"Kawamata M","year":"2023","unstructured":"Kawamata M, Suzuki HI, Kimura R, Suzuki A. Optimization of Cas9 activity through the addition of cytosine extensions to single-guide RNAs. Nat Biomed Eng. 2023, 7:672-91. 10.1038\/s41551-023-01011-7","journal-title":"Nat Biomed Eng"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S326422","article-title":"Mechanism and applications of CRISPR\/Cas-9-mediated genome editing","volume":"15","author":"Asmamaw M","year":"2021","unstructured":"Asmamaw M, Zawdie B. Mechanism and applications of CRISPR\/Cas-9-mediated genome editing. Biologics. 2021, 15:353-61. 10.2147\/BTT.S326422","journal-title":"Biologics"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2018.1474964","article-title":"Delivering CRISPR: a review of the challenges and approaches","volume":"25","author":"Lino CA","year":"2018","unstructured":"Lino CA, Harper JC, Carney JP, Timlin JA. Delivering CRISPR: a review of the challenges and approaches. Drug Deliv. 2018, 25:1234-57. 10.1080\/10717544.2018.1474964","journal-title":"Drug Deliv"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2011.190","article-title":"Allele-specific RNA interference in FOP silencing the FOP gene","volume":"19","author":"Lowery JW","year":"2012","unstructured":"Lowery JW, Rosen V. Allele-specific RNA interference in FOP silencing the FOP gene. Gene Ther. 2012, 19:701-2. 10.1038\/gt.2011.190","journal-title":"Gene Ther"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3389\/fpls.2020.01237","article-title":"Key mechanistic principles and considerations concerning RNA interference","volume":"11","author":"Svoboda P","year":"2020","unstructured":"Svoboda P. Key mechanistic principles and considerations concerning RNA interference. Front Plant Sci. 2020, 11:1237. 10.3389\/fpls.2020.01237","journal-title":"Front Plant Sci"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-78521-w","article-title":"A comparison of AAV-vector production methods for gene therapy and preclinical assessment","volume":"10","author":"Davidsson M","year":"2020","unstructured":"Davidsson M, Negrini M, Hauser S, et al.. A comparison of AAV-vector production methods for gene therapy and preclinical assessment. Sci Rep. 2020, 10:21532. 10.1038\/s41598-020-78521-w","journal-title":"Sci Rep"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.MDNA3-0052-2014","article-title":"Adeno-associated virus as a mammalian DNA Vector","volume":"3","author":"Salganik M","year":"2015","unstructured":"Salganik M, Hirsch ML, Samulski RJ. Adeno-associated virus as a mammalian DNA Vector. Microbiol Spectr. 2015, 3:10.1128\/microbiolspec.MDNA3-0052-2014","journal-title":"Microbiol Spectr"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang D","year":"2019","unstructured":"Wang D, Tai PW, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019, 18:358-78. 10.1038\/s41573-019-0012-9","journal-title":"Nat Rev Drug Discov"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1038\/s41576-019-0205-4","article-title":"Engineering adeno-associated virus vectors for gene therapy","volume":"21","author":"Li C","year":"2020","unstructured":"Li C, Samulski RJ. Engineering adeno-associated virus vectors for gene therapy. Nat Rev Genet. 2020, 21:255-72. 10.1038\/s41576-019-0205-4","journal-title":"Nat Rev Genet"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2019.153063","article-title":"Gushukang inhibits osteocyte apoptosis and enhances BMP-2\/Smads signaling pathway in ovariectomized rats","volume":"64","author":"Chai S","year":"2019","unstructured":"Chai S, Wan L, Wang JL, Huang JC, Huang HX. Gushukang inhibits osteocyte apoptosis and enhances BMP-2\/Smads signaling pathway in ovariectomized rats. Phytomedicine. 2019, 64:153063. 10.1016\/j.phymed.2019.153063","journal-title":"Phytomedicine"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1210\/en.2013-1155","article-title":"GSK-3\u03b2 function in bone regulates skeletal development, whole-body metabolism, and male life span","volume":"154","author":"Gillespie JR","year":"2013","unstructured":"Gillespie JR, Bush JR, Bell GI, et al.. GSK-3\u03b2 function in bone regulates skeletal development, whole-body metabolism, and male life span. Endocrinology. 2013, 154:3702-18. 10.1210\/en.2013-1155","journal-title":"Endocrinology"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2019.1595283","article-title":"Glycogen synthase kinase-3 beta inhibitors as novel cancer treatments and modulators of antitumor immune responses","volume":"20","author":"Sahin I","year":"2019","unstructured":"Sahin I, Eturi A, De Souza A, Pamarthy S, Tavora F, Giles FJ, Carneiro BA. Glycogen synthase kinase-3 beta inhibitors as novel cancer treatments and modulators of antitumor immune responses. Cancer Biol Ther. 2019, 20:1047-56. 10.1080\/15384047.2019.1595283","journal-title":"Cancer Biol Ther"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M212635200","article-title":"Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium. Evidence for autoregulation of GSK-3","volume":"278","author":"Zhang F","year":"2003","unstructured":"Zhang F, Phiel CJ, Spece L, Gurvich N, Klein PS. Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium. Evidence for autoregulation of GSK-3. J Biol Chem. 2003, 278:33067-77. 10.1074\/jbc.M212635200","journal-title":"J Biol Chem"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1002\/dvdy.387","article-title":"BMP signaling and skeletal development in fibrodysplasia ossificans progressiva (FOP)","volume":"251","author":"Towler OW","year":"2022","unstructured":"Towler OW, Shore EM. BMP signaling and skeletal development in fibrodysplasia ossificans progressiva (FOP). Dev Dyn. 2022, 251:164-77. 10.1002\/dvdy.387","journal-title":"Dev Dyn"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2018.01.002","article-title":"Variant BMP receptor mutations causing fibrodysplasia ossificans progressiva (FOP) in humans show BMP ligand-independent receptor activation in zebrafish","volume":"109","author":"Mucha BE","year":"2018","unstructured":"Mucha BE, Hashiguchi M, Zinski J, Shore EM, Mullins MC. Variant BMP receptor mutations causing fibrodysplasia ossificans progressiva (FOP) in humans show BMP ligand-independent receptor activation in zebrafish. Bone. 2018, 109:225-31. 10.1016\/j.bone.2018.01.002","journal-title":"Bone"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2020.102510","article-title":"The roles of PPAR\u03b3 and its agonists in autoimmune diseases: a comprehensive review","volume":"113","author":"Liu Y","year":"2020","unstructured":"Liu Y, Wang J, Luo S, Zhan Y, Lu Q. The roles of PPAR\u03b3 and its agonists in autoimmune diseases: a comprehensive review. J Autoimmun. 2020, 113:102510. 10.1016\/j.jaut.2020.102510","journal-title":"J Autoimmun"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1702084114","article-title":"Rationally designed PPAR\u03b4-specific agonists and their therapeutic potential for metabolic syndrome","volume":"114","author":"Cox RL","year":"2017","unstructured":"Cox RL. Rationally designed PPAR\u03b4-specific agonists and their therapeutic potential for metabolic syndrome. Proc Natl Acad Sci U S A. 2017, 114:3284-5. 10.1073\/pnas.1702084114","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.4252\/wjsc.v13.i12.1826","article-title":"Application of mesenchymal stem cells derived from human pluripotent stem cells in regenerative medicine","volume":"13","author":"Liu TM","year":"2021","unstructured":"Liu TM. Application of mesenchymal stem cells derived from human pluripotent stem cells in regenerative medicine. World J Stem Cells. 2021, 13:1826-44. 10.4252\/wjsc.v13.i12.1826","journal-title":"World J Stem Cells"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.reth.2019.04.004","article-title":"Insights into the biology of fibrodysplasia ossificans progressiva using patient-derived induced pluripotent stem cells","volume":"11","author":"Nakajima T","year":"2019","unstructured":"Nakajima T, Ikeya M. Insights into the biology of fibrodysplasia ossificans progressiva using patient-derived induced pluripotent stem cells. Regen Ther. 2019, 11:25-30. 10.1016\/j.reth.2019.04.004","journal-title":"Regen Ther"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1510540112","article-title":"Neofunction of ACVR1 in fibrodysplasia ossificans progressiva","volume":"112","author":"Hino K","year":"2015","unstructured":"Hino K, Ikeya M, Horigome K, et al.. Neofunction of ACVR1 in fibrodysplasia ossificans progressiva. Proc Natl Acad Sci U S A. 2015, 112:15438-43. 10.1073\/pnas.1510540112","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02506-3","article-title":"Recapitulation of pro-inflammatory signature of monocytes with ACVR1A mutation using FOP patient-derived iPSCs","volume":"17","author":"Maekawa H","year":"2022","unstructured":"Maekawa H, Jin Y, Nishio M, et al.. Recapitulation of pro-inflammatory signature of monocytes with ACVR1A mutation using FOP patient-derived iPSCs. Orphanet J Rare Dis. 2022, 17:364. 10.1186\/s13023-022-02506-3","journal-title":"Orphanet J Rare Dis"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1089\/cell.2016.0020","article-title":"Generation of induced pluripotent stem cells with substitutes for Yamanaka's four transcription factors","volume":"18","author":"Xiao X","year":"2016","unstructured":"Xiao X, Li N, Zhang D, Yang B, Guo H, Li Y. Generation of induced pluripotent stem cells with substitutes for Yamanaka's four transcription factors. Cell Reprogram. 2016, 18:281-97. 10.1089\/cell.2016.0020","journal-title":"Cell Reprogram"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-021-00637-4","article-title":"Biological importance of OCT transcription factors in reprogramming and development","volume":"53","author":"Kim KP","year":"2021","unstructured":"Kim KP, Han DW, Kim J, Sch\u00f6ler HR. Biological importance of OCT transcription factors in reprogramming and development. Exp Mol Med. 2021, 53:1018-28. 10.1038\/s12276-021-00637-4","journal-title":"Exp Mol Med"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.690112","article-title":"Cancer immunotherapies: from efficacy to resistance mechanisms - not only checkpoint matters","volume":"12","author":"Wang S","year":"2021","unstructured":"Wang S, Xie K, Liu T. Cancer immunotherapies: from efficacy to resistance mechanisms - not only checkpoint matters. Front Immunol. 2021, 12:690112. 10.3389\/fimmu.2021.690112","journal-title":"Front Immunol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman AD","year":"2020","unstructured":"Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020, 20:651-68. 10.1038\/s41577-020-0306-5","journal-title":"Nat Rev Immunol"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1038\/s41536-021-00178-4","article-title":"Macrophages in heterotopic ossification: from mechanisms to therapy","volume":"6","author":"Huang Y","year":"2021","unstructured":"Huang Y, Wang X, Zhou D, Zhou W, Dai F, Lin H. Macrophages in heterotopic ossification: from mechanisms to therapy. NPJ Regen Med. 2021, 6:70. 10.1038\/s41536-021-00178-4","journal-title":"NPJ Regen Med"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-99084-4","article-title":"Modular fluorescent nanoparticle DNA probes for detection of peptides and proteins","volume":"11","author":"Stawicki CM","year":"2021","unstructured":"Stawicki CM, Rinker TE, Burns M, et al.. Modular fluorescent nanoparticle DNA probes for detection of peptides and proteins. Sci Rep. 2021, 11:19921. 10.1038\/s41598-021-99084-4","journal-title":"Sci Rep"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1039\/c8nr02278j","article-title":"Characterization techniques for nanoparticles: comparison and complementarity upon studying nanoparticle properties","volume":"10","author":"Mourdikoudis S","year":"2018","unstructured":"Mourdikoudis S , Pallares RM , Thanh NT . Characterization techniques for nanoparticles: comparison and complementarity upon studying nanoparticle properties. Nanoscale. 2018, 10:12871-934. 10.1039\/c8nr02278j","journal-title":"Nanoscale"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1080\/21678707.2017.1304211","article-title":"Hard targets for a second skeleton: therapeutic horizons for fibrodysplasia ossificans progressiva (FOP)","volume":"5","author":"Kaplan FS","year":"2017","unstructured":"Kaplan FS, Pignolo RJ, Al Mukaddam MM, Shore EM. Hard targets for a second skeleton: therapeutic horizons for fibrodysplasia ossificans progressiva (FOP). Expert Opin Orphan Drugs. 2017, 5:291-4. 10.1080\/21678707.2017.1304211","journal-title":"Expert Opin Orphan Drugs"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00908","article-title":"Fibrodysplasia ossificans progressiva (FOP): a segmental progeroid syndrome","volume":"10","author":"Pignolo RJ","year":"2019","unstructured":"Pignolo RJ, Wang H, Kaplan FS. Fibrodysplasia ossificans progressiva (FOP): a segmental progeroid syndrome. Front Endocrinol (Lausanne). 2019, 10:908. 10.3389\/fendo.2019.00908","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/172507-novel-therapeutic-targets-for-fibrodysplasia-ossificans-progressiva-emerging-strategies-and-future-directions","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T15:02:31Z","timestamp":1707490951000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/172507-novel-therapeutic-targets-for-fibrodysplasia-ossificans-progressiva-emerging-strategies-and-future-directions"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,28]]},"references-count":55,"URL":"https:\/\/doi.org\/10.7759\/cureus.42614","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,28]]}}}